1The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333(5): 1580-1587.
2Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study(ECASS ).JAMA, 1995, 274 (5): 1017-1025.
3Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke:does it work? Stroke, 1992, 23(12): 1826-1839
4Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology, 1992, 42(5): 976-982
5Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke.Part Ⅱ. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke, 1992, 23(5): 632- 640
6Trouillas P, Nighoghossian N, Getenet JC, et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke,Correlations of outcome with clinical and radiological data. Stroke.1996, 27(5): 882-890
7Boysen G, Vorstrup S, Bogousslavsky J. Thrombolysis for stroketine for a consensus. Cerebrovasc Dis, 1996, 6(6): 376-380
8The National Institute of Neurological Disorders and Stroke (NINDS) rt - PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. Stroke,1997, 28(8): 1530-1540
9del Zopper GJ, Higashida RT, Furlah AJ, et al. PROACT: a phase Ⅱ randomized trial of recombinant Pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators.Prolyse in Acute Cerebral Thromboembolism. Stroke, 1998, 29(1 ):4-11.
10Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultra early thrombolytic therapy. AJNR Am J Neuroradiol, 1996, 17(1):79-85.
